Next generation sequencing for biliary tract cancers

References

• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15;122(24):3838–3847.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. ABC-06 | a randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol. 2019;37(15_suppl):4003.
   Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018 Sep 1;24(17):4154–4161.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015 Sep;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab R, Yap TA, Madison R, et al. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 Dec 16;10(1):22087.
   PubMed Web of Science ®Google Scholar
• Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012 May 6;44(6):690–693.
   PubMed Web of Science ®Google Scholar
• Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017 Jul 10;32(1):57–70 e3.
   PubMed Web of Science ®Google Scholar
• Wang A, Wu L, Lin J, et al. Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nat Commun. 2018 Mar 1;9(1):894.
   PubMed Web of Science ®Google Scholar
• Bile Duct Cancer Clinical Trials [Website]. National Cancer Institute; [cited 2021 Feb 10]. Available from: https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/bile-duct-cancer
   Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Jun;21(6):796–807.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671–684.
   PubMed Web of Science ®Google Scholar
• Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020 Oct;31(10):1405–1412.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Meric-Bernstam F, Hollebecque A, et al. 54P Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: subgroup analyses of a phase II study (FOENIX-CCA2). Ann Oncol. 2020;31:S261–S262.
   Web of Science ®Google Scholar
• Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015 May 29;8:58.
   PubMed Web of Science ®Google Scholar
• Bogenberger JM, DeLeon TT, Arora M, et al. Emerging role of precision medicine in biliary tract cancers. NPJ Precis Oncol. 2018;2:21.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Hanna DL, El-Khoueiry AB, et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study. J Clin Oncol. 2021;39(3_suppl)):299.
   Web of Science ®Google Scholar
• Subbiah V, Lassen U, Elez E, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 Sep;21(9):1234–1243.
   PubMed Web of Science ®Google Scholar
• Demols A, Perez-Casanova L, Rocq L, et al. NTRK gene fusions in bilio-pancreatic cancers. J Clin Oncol. 2020;38(15_suppl):e16664–e16664.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Tavolari S, et al. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):441–452.
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Schwerdel D, Dolnik A, et al. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep. 2019 Sep 13;9(1):13261.
   PubMed Web of Science ®Google Scholar
• Mody K, Kasi PM, Yang JD, et al. Circulating Tumor DNA profiling of advanced biliary tract cancers. JCO Precis Oncol. 2019;18;3:Mar.
   Web of Science ®Google Scholar
• Yarlagadda B, Kamatham V, Ritter A, et al. Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma. NPJ Precis Oncol. 2019;3:19.
   PubMed Web of Science ®Google Scholar
• Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017 Mar;7(3):252–263.
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019 Aug;9(8):1064–1079.
   PubMed Web of Science ®Google Scholar
• Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann Oncol. 2020 Nov;31(11):1491–1505.
   PubMed Web of Science ®Google Scholar